17 Needs context
Lowering insulin increases daily resting energy expenditure by 200 to 500 calories.
"a higher metabolic rate by several hundred calories a day when insulin goes down. So the body's just burning a little hotter. The engine is revving higher. So the overall energy expenditure is up, again, by 200 to 500 calories a day." (said at 0:26:38)
The speaker's figures of 200 to ~500 calories per day come from controlled feeding trials evaluating the carbohydrate-insulin model of obesity during weight-loss maintenance. In a randomized trial of 164 adults (Ebbeling et al., 2018), lowering dietary carbohydrate increased total energy expenditure (TEE) by 209 kcal/day in intention-to-treat analysis (278 kcal/day per protocol), and by 308 to 478 kcal/day among participants in the highest tertile of baseline insulin secretion. A subsequent meta-analysis of 29 controlled-feeding studies found that trials lasting longer than 2.5 weeks showed a mean increase of 135 kcal/day on lower-carbohydrate diets. However, this effect applies to total daily energy expenditure (TEE) during weight-loss maintenance rather than resting energy expenditure (REE) alone (which shows smaller changes), and the magnitude and universality of this metabolic advantage remain an area of ongoing debate.
- context: Effects of dietary composition on energy expenditure during weight-loss maintenance. (JAMA 2012) · cited 433x in the literature
"Compared with the pre-weight-loss baseline, the decrease in REE was greatest with the low-fat diet (mean [95% CI], -205 [-265 to -144] kcal/d), intermediate with the low-glycemic index diet (-166 [-227 to -106] kcal/d), and least with the very low-carbohydrate diet (-138 [-198 to -77] kcal/d; overall P = .03; P for trend by glycemic load = .009). The decrease in TEE showed a similar pattern (mean [95% CI], -423 [-606 to -239] kcal/d; -297 [-479 to -115] kcal/d; and -97 [-281 to 86] kcal/d, respectively; overall P = .003; P for trend by glycemic load < .001)." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Effects of a low carbohydrate diet on energy expenditure during weight loss maintenance: r… (BMJ (Clinical research ed.) 2018) · cited 278x in the literature
"Change in total energy expenditure was 91 kcal/d (95% confidence interval -29 to 210) greater in participants assigned to the moderate carbohydrate diet and 209 kcal/d (91 to 326) greater in those assigned to the low carbohydrate diet compared with the high carbohydrate diet. In the per protocol analysis (n=120, P<0.001), the respective differences were 131 kcal/d (-6 to 267) and 278 kcal/d (144 to 411). Among participants in the highest third of pre-weight loss insulin secretion, the difference between the low and high carbohydrate diet was 308 kcal/d in the intention-to-treat analysis and 478 kcal/d in the per protocol analysis (P<0.004)." (abstract, results, passage verified)
pubmedfull study (doi) - context: Do Lower-Carbohydrate Diets Increase Total Energy Expenditure? An Updated and Reanalyzed M… (The Journal of nutrition 2021) · cited 75x in the literature
"Among 6 longer trials, TEE was increased on low-carbohydrate diets (135.4 kcal/d; 95% CI: 72.0, 198.7 kcal/d) with low heterogeneity (I2 = 26.4). Expressed per 10% decrease in carbohydrate as %EI, the TEE effects in shorter and longer trials were -14.5 kcal/d and 50.4 kcal/d, respectively." (abstract, results, passage verified)
pubmedfull study (doi)
Polycystic ovary syndrome (PCOS) is the most common cause of female infertility.
"polycystic ovary syndrome, the most common infertility in women" (said at 0:09:09)
The claim is broadly accurate but requires specific qualification. Polycystic ovary syndrome (PCOS) is established in clinical literature as the most common cause of anovulatory (ovulatory dysfunction) infertility in women, rather than the leading cause of all female infertility across all etiologies (which also include tubal disease, endometriosis, and diminished ovarian reserve).
Breast cancer is the most common cancer in women, and prostate cancer is the most common cancer in men.
"breast and prostate cancers, the two most common cancers in women and men respectively." (said at 0:09:09)
Breast cancer is indeed the most commonly diagnosed cancer among women both globally and regionally. However, whether prostate cancer is the most common cancer in men depends on the geographic population: globally, lung cancer is the most frequently diagnosed cancer in men (followed by prostate cancer), whereas in the United States and many high-income countries, prostate cancer is the most frequently diagnosed non-cutaneous cancer among men.
Studies in the European Journal of Clinical Nutrition showed that a high-carbohydrate, high-saturated-fat diet produced the worst insulin resistance and insulin signaling outcomes.
"it was some groups in Europe in the European Journal of Clinical Nutrition where they had, in the context of a high-carb diet and then manipulating the saturation of fats, the high-carb and high-saturated fat was the worst for insulin resistance and insulin signaling." (said at 0:33:25)
The speaker accurately describes the findings of landmark European dietary intervention research, though the primary multicenter trial was published in Diabetologia (the KANWU study) rather than the European Journal of Clinical Nutrition. In the randomized controlled KANWU trial (n=162 healthy adults), replacing monounsaturated fatty acids with saturated fatty acids significantly impaired insulin sensitivity (-10%), with the impairment concentrated in individuals consuming a total fat intake below the median (<37% of total energy, corresponding to a higher background carbohydrate intake, where insulin sensitivity was 12.5% lower on the saturated fat diet and 8.8% higher on the monounsaturated diet).
- supports: Substituting dietary saturated for monounsaturated fat impairs insulin sensitivity in heal… (Diabetologia 2001) · cited 1123x in the literature
"Insulin sensitivity was significantly impaired on the saturated fatty acid diet (-10%, p = 0.03) but did not change on the monounsaturated fatty acid diet (+2%, NS) (p = 0.05 for difference between diets)... The favourable effects of substituting a monounsaturated fatty acid diet for a saturated fatty acid diet on insulin sensitivity were only seen at a total fat intake below median (37E%). Here, insulin sensitivity was 12.5% lower and 8.8% higher on the saturated fatty acid diet and monounsaturated fatty acid diet respectively (p = 0.03)." (abstract, results, passage verified)
pubmedfull study (doi) - context: Dietary fat, insulin sensitivity and the metabolic syndrome. (Clinical nutrition (Edinburgh, Scotland) 2004) · cited 630x in the literature
"Epidemiological evidence and intervention studies clearly show that in humans saturated fat significantly worsen insulin-resistance, while monounsaturated and polyunsaturated fatty acids improve it through modifications in the composition of cell membranes which reflect at least in part dietary fat composition. A recent multicenter study (KANWU) has shown that shifting from a diet rich in saturated fatty acids to one rich in monounsaturated fat improves insulin sensitivity in healthy people" (abstract, results, passage verified)
pubmedfull study (doi)
Skeletal muscle accounts for roughly 80% of glucose uptake during glucose clearance.
"When if someone's wearing their CGM and they see the glucose come up and down, 80% of that coming down is what's going in to fuel the muscle." (said at 0:46:12)
Under conditions of high physiological hyperinsulinemia (such as during hyperinsulinemic-euglycemic clamp studies), skeletal muscle is well established as the primary site of peripheral insulin-mediated glucose disposal, accounting for approximately 70–80% of total body glucose uptake. However, applying this figure directly to ordinary postprandial glucose curves observed on a continuous glucose monitor (CGM) requires qualification. Following meal ingestion, postprandial glucose homeostasis involves multiple concurrent processes: suppression of endogenous hepatic glucose production, splanchnic (hepatic and gut) glucose uptake, and peripheral disposal across muscle and adipose tissue, meaning skeletal muscle accounts for a smaller proportion (typically 30–50%) of total postprandial glucose clearance than the 80% measured under clamp conditions.
- context: Insulin: The master regulator of glucose metabolism. (Metabolism: clinical and experimental 2022) · cited 324x in the literature
"Following ingestion of an oral glucose load or mixed meal, the plasma glucose concentration rises, insulin secretion by the beta cells is stimulated and the hyperinsulinemia, working in concert with hyperglycemia, causes: (i) suppression of endogenous (primarily reflects hepatic) glucose production, (ii) stimulation of glucose uptake by muscle, liver, and adipocytes, (iii) inhibition of lipolysis leading to a decline in plasma FFA concentration which contributes to the suppression of hepatic glucose production and augmentation of muscle glucose uptake, and (iv) vasodilation in muscle, which contributes to enhanced muscle glucose disposal." (abstract, passage verified)
pubmedfull study (doi)
Atypical antipsychotics with the suffix '-apine' promote weight gain, likely mediated by hypothalamic insulin resistance that reduces satiety signaling.
"And then just for the sake of time, perhaps I just mention the atypical antipsychotics. Any drug that ends with an -apine at the end of it, the suffix being -apine, is generally going to promote weight gain. That's probably through a central insulin resistance of the hypothalamus. When the hypothalamus becomes insulin resistant, you have a reduced satiety signal and the person's just going to start eating more." (said at 1:16:55)
Atypical antipsychotics ending in the suffix '-apine' (notably clozapine, olanzapine, and quetiapine) carry the highest risk of weight gain and metabolic disruption among psychiatric medications. These agents act centrally within the hypothalamus, disrupting satiety signaling, appetite neuropeptides, and central insulin/glucose pathways. However, framing hypothalamic insulin resistance as the primary driver of increased food intake oversimplifies the mechanism: the dominant, well-established pharmacological triggers of antipsychotic-induced hyperphagia are antagonism of hypothalamic histamine H1 and serotonin 5-HT2C receptors and subsequent hypothalamic AMPK activation, alongside central and peripheral metabolic disturbances.
- context: Drug induced weight gain, an impediment to successful pharmacotherapy: focus on antipsycho… (Current drug targets 2004) · cited 99x in the literature
"Unfortunately, some of them induce excessive body weight gain (BWG), obesity, hyperglycemia and dyslipidemia in the following order: clozapine approximately equal to olanzapine > quetiapine > risperidone > ziprasidone = aripiprazole. Appetite stimulation is probably the main mechanism of BWG and this is strongly correlated with the APD affinity for H1 (histaminergic) and alpha1 (adrenergic) receptors." (abstract, results, passage verified)
pubmedfull study (doi) - partial: Olanzapine-induced insulin resistance may occur via attenuation of central K ATP channel-a… (Schizophrenia research 2021) · cited 9x in the literature
"Recent work suggests antipsychotics can induce insulin resistance immediately and independently of weight gain, and that this may occur via the central nervous system (CNS). We have previously shown that the highly effective and widely prescribed antipsychotic, olanzapine inhibits CNS insulin-mediated suppression of hepatic glucose production, but the mechanisms remain unknown." (abstract, results, passage verified)
pubmedfull study (doi) - context: Atypical Antipsychotics and Metabolic Syndrome: From Molecular Mechanisms to Clinical Diff… (Pharmaceuticals (Basel, Switzerland) 2021) · cited 249x in the literature
"In fact, AAPs interfere profoundly with glucose and lipid homeostasis acting mostly on hypothalamus, liver, pancreatic β-cells, adipose tissue, and skeletal muscle. Their actions on hypothalamic centers via dopamine, serotonin, acetylcholine, and histamine receptors affect neuropeptides and 5'AMP-activated protein kinase (AMPK) activity, thus producing a supraphysiological sympathetic outflow augmenting levels of glucagon and hepatic glucose production... In clinical practice, among AAPs, olanzapine and clozapine are associated with the highest risk of MetS, whereas quetiapine, risperidone, asenapine and amisulpride cause moderate alterations." (abstract, results, passage verified)
pubmedfull study (doi)
Cholesterol synthesis pathways produce an essential component of the mitochondrial electron transport system.
"cholesterol is a precursor to an essential component of the electron transport system. And so, it's no surprise that if people are waging war on cholesterol synthesis, the mitochondria may suffer." (said at 1:15:37)
The statement is biochemically accurate regarding the pathway and its physiological consequences, but contains a slight chemical misstatement: cholesterol itself is not the precursor to components of the electron transport chain. Rather, the mevalonate pathway—the biosynthetic pathway responsible for producing cholesterol—branches off upstream at intermediate isoprenoids (such as farnesyl pyrophosphate) to synthesize ubiquinone (coenzyme Q10), an essential electron carrier in the mitochondrial respiratory chain. Consequently, pharmacological inhibition of cholesterol synthesis using HMG-CoA reductase inhibitors (statins) decreases the production of mevalonate and downstream coenzyme Q10, which can contribute to mitochondrial dysfunction and statin-associated muscle symptoms.
- context: Basic and Clinical Observations of Mevalonate Depletion on the Mevalonate Signaling Pathwa… (Current molecular pharmacology 2017) · cited 12x in the literature
"As a result of this intervention, mevalonate production, formed during cholesterol synthesis, is inhibited. Mevalonate is the precursor to a variety of crucial downstream products, including those involved with the mitochondrial electron transport chain, and localized activation of small GTPases." (abstract, background, passage verified)
pubmedfull study (doi) - context: Effects of statins on mitochondrial pathways. (Journal of cachexia, sarcopenia and muscle 2021) · cited 246x in the literature
"They inhibit β-hydroxy β-methylglutaryl-coenzyme A reductase, i.e. the rate-limiting enzyme in mevalonate pathway, reduce endogenous cholesterol synthesis, and increase low-density lipoprotein clearance by promoting low-density lipoprotein receptor expression mainly in the hepatocytes... Results have shown that statins have several effects on mitochondria including reduction of coenzyme Q10 level, inhibition of respiratory chain complexes, induction of mitochondrial apoptosis" (abstract, results, passage verified)
pubmedfull study (doi)
A study found that South Asian men have subcutaneous adipocytes that are approximately four times larger volumetrically than Caucasian men matched for body size and body fat percentage.
"there's one paper I'm recalling where it took Caucasian men and South Asian men and did an adipose subcutaneous biopsy, and it found that the average South Asian man had adipocytes that were about four times larger volumetrically than the fat cells in the Caucasian at the same body size, same body fat percent." (said at 1:38:50)
The speaker accurately references a study comparing subcutaneous abdominal adipose tissue biopsies between South Asian and Caucasian men (Abate et al., 2007, PMID 17726542). The study found that South Asian men had subcutaneous abdominal adipocyte cross-sectional areas more than twice as large as Caucasian men (3,491 ± 1,393 µm² vs 1,648 ± 864 µm²), which corresponds mathematically to approximately a 3-fold difference in cell volume. However, while the groups were matched for age and BMI, they were not matched for total body fat percentage (South Asian men had significantly higher body fat percentage at 22% vs 15%), though differences in adipocyte size persisted when comparing subgroups matched for subcutaneous abdominal fat mass.
C-reactive protein is a better predictor of heart disease than LDL cholesterol.
"C-reactive protein is a better predictor of heart disease than LDL cholesterol is." (said at 1:46:07)
The claim stems from landmark prospective cohort findings (such as the Women's Health Study of 27,939 women), which found that baseline high-sensitivity C-reactive protein (hs-CRP) exhibited a steeper relative risk gradient across quintiles (RR up to 2.3) for first cardiovascular events than LDL cholesterol (RR up to 1.5) and concluded CRP was a stronger predictor. However, broader multi-cohort individual-participant meta-analyses (e.g., the Emerging Risk Factors Collaboration across >240,000 participants) demonstrate that while CRP is an independent predictor, its addition to standard risk models containing cholesterol metrics provides modest incremental discrimination (increasing the C-index by ~0.0039). Furthermore, LDL cholesterol is an established causal factor in atherogenesis, whereas CRP is a marker of vascular and systemic inflammation, making them complementary rather than mutually exclusive risk markers.
- supports: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the pre… (The New England journal of medicine 2002) · cited 3619x in the literature
"These data suggest that the C-reactive protein level is a stronger predictor of cardiovascular events than the LDL cholesterol level and that it adds prognostic information to that conveyed by the Framingham risk score." (abstract, conclusions, passage verified)
pubmedfull study (doi) - context: C-reactive protein, fibrinogen, and cardiovascular disease prediction. (The New England journal of medicine 2012) · cited 1170x in the literature
"The addition of information on high-density lipoprotein cholesterol to a prognostic model for cardiovascular disease that included age, sex, smoking status, blood pressure, history of diabetes, and total cholesterol level increased the C-index, a measure of risk discrimination, by 0.0050. The further addition to this model of information on CRP or fibrinogen increased the C-index by 0.0039 and 0.0027, respectively (P<0.001)" (abstract, results, passage verified)
pubmedfull study (doi)
4-HNE, a peroxidation metabolite of linoleic acid, inhibits the hyperplasia potential of fat cells and forces hypertrophic fat growth.
"Specifically, when linoleic acid is taken into the cell, one of its peroxide metabolites that it can turn into is a molecule called 4-HNE. And 4-HNE has been shown to inhibit the fat cell's potential for hyperplasia, thus forcing the fat cell to only go down hypertrophy." (said at 1:47:10)
4-Hydroxynonenal (4-HNE) is a well-established lipid peroxidation byproduct of omega-6 polyunsaturated fatty acids, including linoleic acid. In vitro studies using human adipose-derived stem cells, subcutaneous preadipocytes, and cell lines demonstrate that 4-HNE exposure inhibits adipogenic differentiation (the hyperplasia pathway of adipose tissue). When the formation of new fat cells from precursors is impaired, adipose tissue expansion under positive energy balance is driven predominantly by the enlargement (hypertrophy) of existing adipocytes. However, this model is based on cell culture and ex vivo tissue biopsy mechanisms rather than clinical or in vivo whole-body outcome trials.
- supports: PKC-ALDH2 Pathway Plays a Novel Role in Adipocyte Differentiation. (PloS one 2016) · cited 27x in the literature
"Knockdown of ALDH2 expression in 3T3-L1 preadipocytes caused an increase in intracellular 4-HNE, thereby attenuated adipocyte differentiation." (abstract, results, passage verified)
pubmedfull study (doi) - supports: 4-hydroxynonenal causes impairment of human subcutaneous adipogenesis and induction of adi… (Free radical biology & medicine 2017) · cited 70x in the literature
"Short and long-term in vitro treatment of SC preadipocytes with 4-HNE caused inhibition of their growth and increased production of reactive oxygen species (ROS) and antioxidant enzymes. Repeated 4-HNE treatment led to a greater reduction in the adipogenic capacity of preadipocytes" (abstract, results, passage verified)
pubmedfull study (doi) - supports: Accumulation of 4-Hydroxynonenal Characterizes Diabetic Fat and Modulates Adipogenic Diffe… (International journal of molecular sciences 2023) · cited 11x in the literature
"Notably, at concentrations that did not affect cell viability (1 μM), 4-HNE hampered adipogenic ASCs' differentiation through a timely-regulated activation of the Wnt/β-catenin, p38MAPK, ERK1/2- and JNK-mediated pathways." (abstract, results, passage verified)
pubmedfull study (doi)
Dr. Stephen Cunnane's research documented that rapid oxidation of linoleic acid enables the brain to synthesize its own ketones.
"Even Dr. Stephen Cunnane, this incredible man, just a delightful individual, he's done a lot of work documenting the fact that linoleic acid, when it's allowed to just be burned for fuel, burns so high and so rapid that it create—it allows the brain to create its own ketones." (said at 1:49:05)
Dr. Stephen Cunnane's research documented that 18-carbon polyunsaturated fatty acids, including linoleic acid and alpha-linolenic acid, are predominantly metabolized via rapid beta-oxidation rather than being preserved intact. In animal tracer studies (suckling rats and neonatal monkeys), Cunnane and colleagues showed that the oxidized carbon skeletons from linoleate readily generate ketones and acetyl-CoA, which the developing brain utilizes as primary substrates for in situ de novo synthesis of brain cholesterol and fatty acids (carbon recycling). However, this research primarily characterizes linoleate as a systemic ketogenic precursor feeding neonatal brain lipid synthesis rather than demonstrating that the adult human brain directly oxidizes linoleic acid to produce ketones for its own general energetic needs.
Dr. Christopher Ramsden at the NIH published research showing that soybean oil has become the leading source of fat calories in the human diet.
"Dr. Christopher Ramsden at the NIH a number of years ago published a report finding that soybean oil has become the number one consumed source of fat calories in the human diet." (said at 1:52:12)
Dr. Christopher Ramsden and colleagues at the NIH co-authored a landmark 2011 study analyzing historical food disappearance data in the United States from 1909 to 1999 (Blasbalg et al., Am J Clin Nutr). They found that per capita consumption of soybean oil increased more than 1,000-fold over the 20th century, becoming by far the largest source of dietary linoleic acid and added fat in the American diet. However, the study specifically evaluated the United States diet using USDA economic disappearance data, rather than the global 'human diet'.
A recently published study found that the risk of developing blindness is more than double in patients taking high-dose GLP-1 receptor agonists.
"with GLP-1, in fact, it's worth noting another paper was just published this week finding that the risk of blindness doubles—more than doubles—in people on high-dose GLP-1s. Paper was just published. So you look at the degree of blindness that occurs in adults, and those using the drug, it was more than twice the risk of developing blindness." (said at 2:29:40)
The speaker is referencing a widely publicized July 2024 observational cohort study published in JAMA Ophthalmology (Hathaway et al.), which investigated the link between semaglutide (a GLP-1 receptor agonist) and nonarteritic anterior ischemic optic neuropathy (NAION), a condition causing sudden optic nerve-related vision loss. That study found a substantially elevated risk of NAION among patients prescribed semaglutide compared to non-GLP-1 medications, both in type 2 diabetes (hazard ratio 4.28) and in overweight/obesity (hazard ratio 7.64). However, characterizing this finding as a general doubling of overall 'blindness' requires important context: NAION is a specific and relatively rare form of optic neuropathy, not overall blindness from all causes. Furthermore, the findings stem from retrospective observational data from a single academic neuro-ophthalmology referral center and demonstrate an association rather than proven causality.
- context: Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide… (JAMA ophthalmology 2024) · cited 286x in the literature
"In the population with T2D, 17 NAION events occurred in patients prescribed semaglutide vs 6 in the non-GLP-1 RA antidiabetes cohort. The cumulative incidence of NAION for the semaglutide and non-GLP-1 RA cohorts over 36 months was 8.9% (95% CI, 4.5%-13.1%) and 1.8% (95% CI, 0%-3.5%), respectively. A Cox proportional hazards regression model showed higher risk of NAION for patients receiving semaglutide (hazard ratio [HR], 4.28; 95% CI, 1.62-11.29); P < .001). In the population of patients who were overweight or obese, 20 NAION events occurred in the prescribed semaglutide cohort vs 3 in the non-GLP-1 RA cohort... A Cox proportional hazards regression model showed a higher risk of NAION for patients prescribed semaglutide (HR, 7.64; 95% CI, 2.21-26.36; P < .001)." (abstract, results, passage verified)
pubmedfull study (doi)
Patients on semaglutide undergoing general anesthesia have been found to retain food in their stomach despite fasting for 24 hours.
"like people who go through general surgery and have to be put under for general anesthesia, they found that normally you tell the person, "Don't eat for 24 hours," and their stomach's empty, so they're not going to vomit food up while they're asleep. But they found that if people were on semaglutide, the food was still there and they would still have food in their stomach even though they hadn't eaten for 24 hours." (said at 2:03:00)
The core claim is backed by clinical research: multiple prospective gastric ultrasound and endoscopic studies demonstrate that patients taking semaglutide frequently retain solid food and increased residual gastric content before general anesthesia or sedation, despite adhering to fasting protocols. However, standard preoperative fasting guidelines typically require 6 to 8 hours of fasting for solid food prior to elective surgery, rather than a mandatory 24-hour fast, though semaglutide-induced delayed gastric emptying can cause solid food to remain in the stomach well past standard fasting windows.
- supports: Relationship between perioperative semaglutide use and residual gastric content: A retrosp… (Journal of clinical anesthesia 2023) · cited 249x in the literature
"Increased RGC was observed in 27 (6.7%) patients, being 8 (24.2%) in the SG and 19 (5.1%) in the NSG (p < 0.001)." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Relationship between residual gastric content and peri-operative semaglutide use assessed … (Anaesthesia 2024) · cited 64x in the literature
"Increased residual gastric content was found in 43/107 patients (40%) in the semaglutide group and 3/113 (3%) in the non-semaglutide group (p < 0.001)." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Gastric ultrasound in patients receiving semaglutide: a prospective, multicentre, matched … (Anaesthesia 2026) · cited 12x in the literature
"A full stomach was observed in 21/43 (49%) of patients receiving semaglutide treatment compared with 8/44 (18%) of controls (odds ratio 4.29, 95%CI 1.63-11.29, p = 0.003). Solid gastric contents were significantly more frequent in patients receiving semaglutide treatment (18/43 (42%)) compared with controls (3/44 (7%), odds ratio 9.85, 95%CI 2.57-37.76, p < 0.001)." (abstract, results, passage verified)
pubmedfull study (doi)
In diabetic retinopathies and nephropathies, excess intracellular glucose is diverted into the sorbitol pathway, where sorbitol accumulation creates an osmotic gradient causing hydropic degeneration and cell rupture.
"And if there's so much glycolysis happening that it starts to inhibit entry into the glycolytic pathway, then you divert the glucose into the sorbitol pathway. Now you have glucose turning into sorbitol, which the cell can't do anything with, and so sorbitol begins to accumulate in the cell and that starts to increase the osmotic gradient into the cell. And now you have basically a water balloon that's getting overfull, and you have this what's called hydropic degeneration, where you basically force water into the cell because of this glucose metabolite, and then the cell can burst. And this is a large part of the problem with macular degeneration and retinopathies. In the nephropathies of the kidney, the main mechanism whereby the glucose is damaging, or one of the main mechanisms, is the conversion of the glucose into sorbitol." (said at 2:38:31)
The speaker correctly identifies the polyol (sorbitol) pathway as a key mechanism in hyperglycemia-induced diabetic microvascular complications, including diabetic retinopathy and nephropathy. Under hyperglycemic conditions, excess intracellular glucose is reduced to sorbitol by aldose reductase, leading to intracellular sorbitol accumulation, osmotic swelling/stress, and oxidative stress. However, the claim oversimplifies and conflates aspects of the mechanism: classic osmotic swelling leading to cell rupture (e.g. hydropic changes/cataract formation) was primarily demonstrated in the lens (cataractogenesis) and early polyol research, whereas in diabetic retinopathy and nephropathy, polyol pathway flux causes cellular damage primarily through osmotic stress, oxidative stress (NADPH depletion and altered NADH/NAD+ redox ratio), and downstream inflammatory/metabolic signaling rather than simple physical ballooning and cell rupture. Additionally, the speaker erroneously mentions macular degeneration (age-related macular degeneration is a distinct pathology from diabetic retinopathy, though diabetic macular edema occurs).
- supports: Aldose Reductase: a cause and a potential target for the treatment of diabetic complicatio… (Archives of pharmacal research 2021) · cited 153x in the literature
"In this hyperglycaemic condition, aldose reductase overexpresses and leads to further complications of diabetes through the polyol pathway. Glucose metabolism-related disorders are the accumulation of sorbitol, overproduction of NADH and fructose, reduction in NAD + , and excessive NADPH usage, leading to diabetic pathogenesis and its complications such as retinopathy, neuropathy, and nephropathy. Accumulation of sorbitol results in the alteration of osmotic pressure and leads to osmotic stress." (abstract, passage verified)
pubmedfull study (doi) - supports: The Role of Aldose Reductase in Polyol Pathway: An Emerging Pharmacological Target in Diab… (Current pharmaceutical biotechnology 2024) · cited 37x in the literature
"In diabetic conditions, the aldose reductase enzyme converts glucose into sorbitol using nicotinamide adenine dinucleotide phosphate as a cofactor. It is a key enzyme in polyol pathway which is a surrogate course of glucose metabolism... intracellular accumulation of sorbitol which is involved in secondary diabetic complications, such as neuropathy, cataractogenesis, nephropathy, retinopathy and cardiovascular pathogenesis. Osmotic upset and oxidative stress are produced by aldose reductase via the polyol pathway." (abstract, passage verified)
pubmedfull study (doi)
Skeletal muscle tissue does not express glucagon receptors.
"Muscle doesn't have glucagon receptors. Like, it's very much tissue specific." (said at 2:44:42)
Classically and functionally in human physiology, skeletal muscle does not respond to glucagon or express physiologically significant glucagon receptors, which explains why glucagon stimulates glycogenolysis in the liver but not in skeletal muscle. However, stating that muscle completely lacks glucagon receptors requires context: sensitive molecular profiling studies have detected low/basal levels of glucagon receptor (GCGR) mRNA transcripts in skeletal muscle tissue.
- context: Glucagon receptor mRNA distribution in rat tissues. (Peptides 1995) · cited 119x in the literature
"In liver, kidney, heart, adipose tissue, spleen, pancreatic islets, ovary, and thymus, glucagon receptor mRNA expression was found to be relatively abundant whereas lower levels were detected in stomach, small intestine, adrenal gland, thyroid, and skeletal muscle." (abstract, results, passage verified)
pubmedfull study (doi)
Glucose-derived polyols such as sorbitol and mannitol cannot passively cross cell membranes.
"these derivatives of glucose, like sorbitol or mannitol, they can't move across cell membranes." (said at 2:43:41)
Glucose-derived polyols like sorbitol and mannitol have very low passive lipid bilayer permeability, which explains why sorbitol accumulates intracellularly during hyperglycemia (causing osmotic stress) and why mannitol acts as an extracellular osmotic agent. However, claiming that they absolutely cannot move across cell membranes requires qualification: several cell types possess carrier-mediated transport mechanisms, including sorbitol permeases, volume-activated channels, and low-affinity transport via hexose transport systems.
Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.